Skip to content

Study · Ex vivo tissue · 1985

1 result

Interleukin-2 and aging: decreased interleukin-2 production in healthy older people does not correlate with reduced helper cell numbers or antibody response to influenza vaccine and is not corrected in vitro by thymosin alpha 1.

Ershler WB, Moore AL, Roessner K, Ranges GE

Immunopharmacology1 Aug 1985Cited by 16 (Europe PMC)

PMID2932408 (opens in a new tab)DOI10.1016/0162-3109(85)90054-2 (opens in a new tab)PepBankPUB-02932408
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In lymphocytes from healthy volunteers, thymosin alpha‑1 had no consistent effect on interleukin-2 production in vitro.

    In plain wordsIn lab tests on human lymphocytes, thymosin alpha‑1 had no consistent effect on interleukin-2 production.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeInterleukin-2 production in vitro
    Study

    humann: not reported in source

    lymphocytes from healthy young and old volunteers
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1 did not have a consistent effect on interleukin-2 production.
    2 context sentences
    Summary · context
    The in vitro effect of thymosin alpha 1 on interleukin-2 production was also measured.
    Summary · context
    The capacity of lymphocytes obtained from healthy young or old volunteers to produce interleukin-2 was measured and the results were compared with other measures of immune function.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.